JP2006089403A - Ophthalmic composition for taking out contact lens - Google Patents

Ophthalmic composition for taking out contact lens Download PDF

Info

Publication number
JP2006089403A
JP2006089403A JP2004276179A JP2004276179A JP2006089403A JP 2006089403 A JP2006089403 A JP 2006089403A JP 2004276179 A JP2004276179 A JP 2004276179A JP 2004276179 A JP2004276179 A JP 2004276179A JP 2006089403 A JP2006089403 A JP 2006089403A
Authority
JP
Japan
Prior art keywords
contact lens
ophthalmic composition
ophthalmic
solution
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004276179A
Other languages
Japanese (ja)
Other versions
JP2006089403A5 (en
JP4642420B2 (en
Inventor
Hironori Fujita
博紀 藤田
Ritsuko Nakamura
律子 中村
Hiroshi Aki
博 安藝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Priority to JP2004276179A priority Critical patent/JP4642420B2/en
Publication of JP2006089403A publication Critical patent/JP2006089403A/en
Publication of JP2006089403A5 publication Critical patent/JP2006089403A5/ja
Application granted granted Critical
Publication of JP4642420B2 publication Critical patent/JP4642420B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

<P>PROBLEM TO BE SOLVED: To obtain an ophthalmic composition for enabling a contact lens to be easily taken out without adding excessive force and without using tools such as a sucker and a dropping pipet even if the contact lens adheres to the eye. <P>SOLUTION: This ophthalmic composition for taking out the contact lens is an aqueous composition having 0.01-0.12 or 0.29-0.56 ion strength, and preferably further contains at least one kind of medicinal component selected from a cornea-protecting agent, vitamins and amino acids. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

本発明は、コンタクトレンズ取り外し用眼科組成物に関する。   The present invention relates to an ophthalmic composition for removing contact lenses.

コンタクトレンズを目から取り外すには、通常、ソフトコンタクトレンズの場合には指でつまんで外し、ハードコンタクトレンズの場合には指で目尻を引っ張って上下の眼瞼でコンタクトレンズをはさみ、まばたきをすることで外す方法が一般的である。また、スポイト先端部にコンタクトレンズ吸着部を備えたコンタクト吸引脱着器(特許文献1参照)や吸盤部を設けたコンタクトレンズ取り外し具(特許文献2参照)等の器具を用いてコンタクトレンズを吸着させて取り外す方法も提案されている。しかし、長時間の装用あるいは涙液の分泌不足等によってコンタクトレンズが角膜に粘着し、コンタクトレンズを取り外しにくくなる場合がある。このような状況下で上記のような通常の取り外し方法を用いると、指や器具によって過度に力を加えてコンタクトレンズを外すことになり易く、コンタクトレンズを損傷する虞があるほか、角膜、結膜や眼瞼を傷つける虞がある。   To remove a contact lens from the eye, usually remove it by pinching it with a finger in the case of a soft contact lens, and in the case of a hard contact lens, pull the corner of the eye with a finger and pinch the contact lens with the upper and lower eyelids to blink The method of removing by is common. In addition, the contact lens can be adsorbed by using a tool such as a contact suction desorption device (see Patent Document 1) having a contact lens suction section at the tip of a dropper or a contact lens removing tool (see Patent Document 2) having a suction cup. A method of removing it is also proposed. However, there are cases where the contact lens adheres to the cornea due to prolonged wearing or insufficient secretion of tears, making it difficult to remove the contact lens. Under such circumstances, if the above normal removal method is used, the contact lens is likely to be removed by applying excessive force with a finger or an instrument, and the contact lens may be damaged. There is a risk of injury to the eyelids.

コンタクトレンズ装着液(特許文献3参照)や、コンタクトレンズ装用眼の安全および装用感を向上させる点眼液(特許文献4参照)は知られているが、コンタクトレンズの取り外しを容易にするための眼科組成物は知られていない。   Although contact lens mounting liquid (see Patent Document 3) and eye drops (see Patent Document 4) that improve the safety and wearing feeling of contact lens wearing eyes are known, ophthalmology for facilitating the removal of contact lenses The composition is not known.

特開2003−255276号公報JP 2003-255276 A 特開平10−197832号公報JP-A-10-197832 特開2003−66383号公報JP 2003-66383 A 特開昭61−246119号公報Japanese Patent Laid-Open No. 61-246119

上記背景において、本発明は、コンタクトレンズが眼に粘着している場合でも、過度に力を加えることなく、また、吸盤やスポイド等の器具を用いることなしに、容易にコンタクトレンズを取り外せるようにするための眼科組成物を提供することを目的とする。   In the above background, the present invention allows the contact lens to be easily removed without applying excessive force or using an instrument such as a suction cup or a spoid even when the contact lens is adhered to the eye. An object of the present invention is to provide an ophthalmic composition for the purpose.

本発明者は、上記目的の達成に向けた検討の結果、イオン強度が0.01〜0.12または0.29〜0.56である水性組成物(水溶液)をコンタクトレンズ装着眼に適用することにより、コンタクトレンズを容易に取り外すことが可能となることを見出し、さらに研究を進めて本発明を完成させた。   As a result of studies aimed at achieving the above object, the present inventor applies an aqueous composition (aqueous solution) having an ionic strength of 0.01 to 0.12 or 0.29 to 0.56 to the eye wearing a contact lens. As a result, it has been found that the contact lens can be easily removed, and further research has been made to complete the present invention.

すなわち本発明は、以下を提供するものである。
(1)イオン強度が0.01〜0.12又は0.29〜0.56の水性組成物である、コンタクトレンズ取り外し用眼科組成物、
(2)角膜保護剤、ビタミン類、アミノ酸からなる群から選択される少なくとも1種の医薬成分を更に含有してなる、上記(1)記載の眼科組成物、及び
(3)点眼剤である上記(1)又は(2)記載の眼科組成物。
That is, the present invention provides the following.
(1) An ophthalmic composition for removing a contact lens, which is an aqueous composition having an ionic strength of 0.01 to 0.12 or 0.29 to 0.56,
(2) The ophthalmic composition according to the above (1), further comprising at least one pharmaceutical ingredient selected from the group consisting of a corneal protective agent, vitamins and amino acids, and (3) the above-mentioned eye drop The ophthalmic composition according to (1) or (2).

本発明によれば、表面に角膜に粘着して従来の方法では取り外し難くなったコンタクトレンズの取り外しが容易となるため、角膜、結膜や眼瞼を傷つけたり、コンタクトレンズを損傷する虞を実質的になくすことができる。   According to the present invention, the contact lens that adheres to the cornea on the surface and becomes difficult to remove by the conventional method can be easily removed, so there is substantially no risk of damaging the cornea, conjunctiva or eyelid, or damaging the contact lens. Can be eliminated.

本発明において、「コンタクトレンズ取り外し用眼科組成物」とは、眼に装着されているコンタクトレンズを取り外す際に、取り外しを容易にする目的で眼に適用される組成物をいう。   In the present invention, the “ophthalmic composition for removing a contact lens” refers to a composition applied to the eye for the purpose of facilitating the removal when the contact lens attached to the eye is removed.

本発明の眼科組成物の形態は、コンタクトレンズ装用眼に適用し易いものであればよく、好ましくは点眼剤である。点眼剤としては点眼液、洗眼液等が挙げられるが、とりわけ点眼液が好ましい。   The ophthalmic composition of the present invention may be in any form as long as it can be easily applied to a contact lens wearing eye, and is preferably an eye drop. Examples of eye drops include eye drops, eye washes, and the like, and eye drops are particularly preferable.

本発明の眼科組成物は、レンズのタイプを特に限定することなく、ソフトコンタクトレンズ、ハードコンタクトレンズおよび酸素透過性ハードコンタクトレンズのいずれにも適用できる。ソフトコンタクトレンズとしては、FDA(米連邦食品医薬品局)の分類による、非イオン性素材で含水率50%未満(低含水率)のグループI、非イオン性素材で含水率50%以上(高含水率)のグループII、イオン性素材で低含水率のグループIII、およびイオン性素材で高含水率のグループIVの各ソフトコンタクトレンズが挙げられるが、これらのうちでも本発明の眼科組成物は、グループIVのソフトコンタクトレンズに取り分け好適に使用される。   The ophthalmic composition of the present invention can be applied to any of soft contact lenses, hard contact lenses, and oxygen-permeable hard contact lenses without any particular limitation on the lens type. Soft contact lenses are group I of non-ionic materials with a moisture content of less than 50% (low moisture content) according to the FDA (Federal Food and Drug Administration) classification, nonionic materials with a moisture content of 50% or more (high moisture content) Ratio) group II, ionic material low water content group III, and ionic material high water content group IV soft contact lenses, among these, the ophthalmic composition of the present invention, It is preferably used for group IV soft contact lenses.

本明細書中におけるイオン強度は、下記式で定義される。
イオン強度=1/2ΣCiZi22
(ここで、Ciは溶液中で解離しているイオン種iのモル濃度、Ziはイオン種iの電荷数である。)
The ionic strength in this specification is defined by the following formula.
Ionic strength = 1 / 2ΣCiZi2 2
(Where Ci is the molar concentration of the ionic species i dissociated in the solution, and Zi is the number of charges of the ionic species i.)

本発明の眼科組成物のイオン強度の範囲は、0.01〜0.12または0.29〜0.56である。   The ionic strength range of the ophthalmic composition of the present invention is 0.01-0.12 or 0.29-0.56.

本発明の眼科組成物において、イオン強度を上記範囲に調整するために好ましく用いられる化合物の例としては、水溶性の無機塩類が挙げられ、具体的には例えば、塩化ナトリウム、塩化カリウム、塩化カルシウム、塩化マグネシウム等が挙げられるが、これらに限定されない。   In the ophthalmic composition of the present invention, examples of the compound preferably used for adjusting the ionic strength to the above range include water-soluble inorganic salts, specifically, for example, sodium chloride, potassium chloride, calcium chloride. , Magnesium chloride and the like, but are not limited thereto.

本発明の眼科組成物は、緩衝剤およびpH調整剤によりpH4〜9、好ましくは5〜8となるよう調整される。使用される緩衝剤の例としては、クエン酸ナトリウム、酢酸ナトリウム、ホウ酸、ε−アミノカプロン酸等とそれらの塩とからなるものが挙げられるが、これらに限定されない。pH調整剤としては、塩酸、酢酸、クエン酸、水酸化ナトリウム、水酸化カリウム等が挙げられるが、これらに限定されない。   The ophthalmic composition of the present invention is adjusted to have a pH of 4 to 9, preferably 5 to 8, with a buffer and a pH adjuster. Examples of the buffer used include, but are not limited to, those composed of sodium citrate, sodium acetate, boric acid, ε-aminocaproic acid and the like and salts thereof. Examples of the pH adjuster include hydrochloric acid, acetic acid, citric acid, sodium hydroxide, potassium hydroxide and the like, but are not limited thereto.

本発明の眼科組成物において、水溶性無機塩類、緩衝剤およびpH調整剤は、イオン強度が前記範囲内となるような量で用いればよく、その限りにおいて、それらの組合せや割合は、特に制限されない。   In the ophthalmic composition of the present invention, the water-soluble inorganic salts, the buffering agent and the pH adjuster may be used in such an amount that the ionic strength is within the above range, and as long as the combination and ratio thereof are not particularly limited. Not.

また、本発明の眼科組成物には、本発明の目的に反しない限り、保存剤(例えばパラオキシ安息香酸エステル類、クロロブタノール、ベンジルアルコール、デヒドロ酢酸ナトリウム、エデト酸ナトリウム、塩化ベンザルコニウム、塩化ベンゼトニウム、ソルビン酸またはその塩等)、安定化剤(例えば亜硫酸水素ナトリウム、チオ硫酸ナトリウム、エデト酸ナトリウム、アスコルビン酸、ジブチルヒドロキシトルエン等)、水溶性高分子(ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルアルコール、ポリビニルピロリドン等)、清涼化剤(例えばメントール、カンフル、ボルネオール等)、界面活性剤(例えばポリソルベート80、ポリオキシエチレン硬化ヒマシ油60、チロキサポール等)等の添加剤を適宜含有させてもよい。   In addition, the ophthalmic composition of the present invention contains a preservative (eg, paraoxybenzoates, chlorobutanol, benzyl alcohol, sodium dehydroacetate, sodium edetate, benzalkonium chloride, Benzethonium, sorbic acid or its salt, etc.), stabilizers (eg sodium bisulfite, sodium thiosulfate, sodium edetate, ascorbic acid, dibutylhydroxytoluene, etc.), water-soluble polymers (hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl) Methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, etc.), cooling agents (eg, menthol, camphor, borneol, etc.), surfactants (eg, polysorbate 80, polyoxyethylene hydrogenated castor oil 60, Additives, etc.) and the like Rokisaporu may appropriately be contained.

さらに、本発明の眼科組成物には、本発明の目的に反しない限り、従来の眼科組成物に配合できる医薬成分、例えば、グリチルリチン酸二カリウム,アラントイン等の抗炎症薬、塩酸ジフェンヒドラミン、マレイン酸クロルフェニラミン等の抗ヒスタミン薬、コンドロイチン硫酸ナトリウム、ヒアルロン酸ナトリウム等の角膜保護薬、α−トコフェロール、ピリドキシン等のビタミン類、アミノエチルスルホン酸、アスパラギン酸またはその塩等のアミノ酸、塩酸エピネフリン、塩酸ナファゾリン、塩酸テトラヒドロゾリン等の充血除去薬、メチル硫酸ネオスチグミン等の副交感神経作用薬を含有させてもよい。これらのうち、含有させるのが特に好ましい医薬成分は、角膜保護薬、ビタミン類およびアミノ酸類である。   Further, in the ophthalmic composition of the present invention, pharmaceutical ingredients that can be blended in the conventional ophthalmic composition, for example, anti-inflammatory drugs such as dipotassium glycyrrhizinate and allantoin, diphenhydramine hydrochloride, maleic acid, etc. Antihistamines such as chlorpheniramine, corneal protective agents such as sodium chondroitin sulfate and sodium hyaluronate, vitamins such as α-tocopherol and pyridoxine, amino acids such as aminoethylsulfonic acid, aspartic acid or its salts, epinephrine hydrochloride, hydrochloric acid A decongestant such as naphazoline and tetrahydrozoline hydrochloride and a parasympathomimetic agent such as neostigmine methyl sulfate may be included. Among these, particularly preferred pharmaceutical ingredients to be included are corneal protective agents, vitamins and amino acids.

これらの医薬成分は、従来の眼科組成物に慣用されている濃度で含有させればよく、そのような濃度は当業者に周知である。具体的には医薬成分の種類によって異なるが、それぞれの医薬成分の薬理効果を達成し得る濃度で含有させればよく、一般的には、例えば角膜保護薬は約0.01〜約1w/v%程度、ビタミン類は約0.001〜約0.5w/v%程度、アミノ酸は約0.01〜約1w/v%程度とすればよい。   These pharmaceutical ingredients may be contained at concentrations conventionally used in conventional ophthalmic compositions, and such concentrations are well known to those skilled in the art. Specifically, it varies depending on the kind of the pharmaceutical ingredient, but it may be contained at a concentration that can achieve the pharmacological effect of each pharmaceutical ingredient. In general, for example, the corneal protective agent is about 0.01 to about 1 w / v. %, Vitamins about 0.001 to about 0.5 w / v%, amino acids about 0.01 to about 1 w / v%.

本発明の眼科組成物は、通常の点眼剤の慣用的な製造方法に従って製造すればよく、例えば第14改正日本薬局方、製剤総則の点眼剤に記載された方法で製造することができる。   The ophthalmic composition of the present invention may be produced according to a conventional production method for ordinary eye drops, and can be produced, for example, by the method described in the eye drops of the 14th revised Japanese Pharmacopoeia, General Rules for Preparations.

角膜表面に粘着したコンタクトレンズに対して、本発明の眼科組成物を、例えば点眼液として使用する場合、コンタクトレンズ装着眼に2〜3滴点眼すれば、その後、器具等を用いない通常の方法により、また、過度に力をかけることなく、コンタクトレンズを容易に取り外すことができる。   When the ophthalmic composition of the present invention is used as an ophthalmic solution for a contact lens adhered to the corneal surface, for example, if 2 to 3 drops are instilled into the contact lens wearing eye, then a normal method without using an instrument or the like In addition, the contact lens can be easily removed without applying excessive force.

以下に、実施例および試験例を挙げて本発明をさらに詳細に説明するが、これらは単なる例示であり、本発明がこれらにより限定されることは意図しない。   The present invention will be described in more detail below with reference to examples and test examples, but these are merely examples and are not intended to limit the present invention.

[試験例1]ソフトコンタクトレンズの直径に及ぼす影響
(試験方法)
FDA分類によるグループIVのソフトコンタクトレンズであるワンデーアキュビュー(ジョンソン・エンド・ジョンソン社製,ベースカーブ:9.0mm,度数:−3.00,レンズ径14.2mm)を用いた。コンタクトレンズを、室温にてpH7.4のリン酸緩衝生理食塩水(PBS)に5分間浸漬した後、直径を測定した。次いで、コンタクトレンズを、表1及び表2の何れかの試験液が入ったシャーレに室温にて5分間浸漬した後、再び直径を測定した。この操作を順次繰り返し行い、下記式により、コンタクトレンズ直径の変化量および変化率を算出した。
[Test Example 1] Influence on diameter of soft contact lens (test method)
One-Day Accuview (manufactured by Johnson & Johnson, base curve: 9.0 mm, power: −3.00, lens diameter 14.2 mm), which is a group IV soft contact lens according to FDA classification, was used. The contact lens was immersed in phosphate buffered saline (PBS) at pH 7.4 for 5 minutes at room temperature, and then the diameter was measured. Next, the contact lens was immersed in a petri dish containing any one of the test solutions shown in Tables 1 and 2 at room temperature for 5 minutes, and then the diameter was measured again. This operation was sequentially repeated, and the change amount and change rate of the contact lens diameter were calculated according to the following formula.

コンタクトレンズ直径の変化量(mm)=〔各試験液浸漬後のコンタクトレンズ直径〕−〔PBS浸漬後のコンタクトレンズ直径〕
コンタクトレンズ直径の変化率(%)=〔各試験液浸漬後のコンタクトレンズ直径〕/〔PBS浸漬後のコンタクトレンズ直径〕×100
Contact lens diameter change (mm) = [Contact lens diameter after immersion in each test solution] − [Contact lens diameter after PBS immersion]
Contact lens diameter change rate (%) = [contact lens diameter after immersion in each test solution] / [contact lens diameter after PBS immersion] × 100

Figure 2006089403
Figure 2006089403

Figure 2006089403
Figure 2006089403

(試験結果)
試験結果を表3および表4に示す。
(Test results)
The test results are shown in Tables 3 and 4.

Figure 2006089403
Figure 2006089403

Figure 2006089403
Figure 2006089403

表3および表4に示したように、実施例1〜5の試験液に浸漬したコンタクトレンズは直径が大きくなり、膨潤した。これは、コンタクトレンズのベースカーブの値が大きくなった(すなわち、カーブが緩くなった)ことを示唆するものである。また、実施例6〜12の試験液に浸漬したコンタクトレンズは直径が小さくなり、収縮した。これは、コンタクトレンズのベースカーブの値が小さくなった(すなわち、カーブが鋭くなった)ことを示すものである。これらの結果から、低イオン強度あるいは高イオン強度の溶液である本発明のコンタクトレンズ取り外し用眼科組成物との接触によってコンタクトレンズのベースカーブが可逆的に顕著に変化し、角膜表面のカーブと合わなくなってコンタクトレンズが角膜表面から部分的に浮き上がる形となり、角膜表面とコンタクトレンズとの接触面積が小さくなることにより、コンタクトレンズが外し易くなると考えられる。   As shown in Tables 3 and 4, the contact lenses soaked in the test solutions of Examples 1 to 5 increased in diameter and swollen. This suggests that the value of the base curve of the contact lens has increased (that is, the curve has become loose). In addition, the contact lenses immersed in the test solutions of Examples 6 to 12 were reduced in diameter and contracted. This indicates that the value of the base curve of the contact lens has become smaller (that is, the curve has become sharper). From these results, the base curve of the contact lens reversibly changes remarkably by contact with the ophthalmic composition for removing a contact lens of the present invention, which is a low ionic strength or high ionic strength solution, and matches the curve of the corneal surface. It is considered that the contact lens is lifted partially from the corneal surface, and the contact area between the corneal surface and the contact lens is reduced, so that the contact lens can be easily removed.

[試験例2]角膜の重量変化
(試験方法)
ウサギ(ダッチ種)を用いた。安楽死させた後、眼球を摘出し、直ちに角膜を取り出した。取り出した角膜の表面の水分をふき取り、重量を測定し、初期値とした。この角膜を次の各試験液10mLが入ったビーカーに浸漬し、5分後に角膜を取り出し、表面の水分をふき取った後、角膜重量を測定した(n=3)。初期値を100とし、各試験液に浸漬した後の角膜の重量比を求めた。
(試験液)
対照液:精製水
試験液A:0.9%塩化ナトリウム水溶液(イオン強度:0.154)
試験液B:3.0%塩化ナトリウム水溶液(イオン強度:0.513)
[Test Example 2] Weight change of cornea (test method)
Rabbits (Dutch species) were used. After euthanasia, the eyeball was removed and the cornea was immediately removed. The water on the surface of the cornea taken out was wiped off, and the weight was measured to obtain an initial value. The cornea was immersed in a beaker containing 10 mL of each of the following test solutions, and after 5 minutes, the cornea was taken out and the surface moisture was wiped off. Then, the cornea weight was measured (n = 3). The initial value was set to 100, and the weight ratio of the cornea after being immersed in each test solution was determined.
(Test solution)
Control solution: Purified water Test solution A: 0.9% sodium chloride aqueous solution (ionic strength: 0.154)
Test solution B: 3.0% sodium chloride aqueous solution (ionic strength: 0.513)

(試験結果)
試験結果を図1に示す。
(Test results)
The test results are shown in FIG.

図1に示したように、高イオン強度の試験液Bでは角膜重量は有意に減少した。これは、角膜中から水分が減少したことを示す。この結果から、高イオン強度の溶液によってコンタクトレンズと角膜との間に角膜から水分が滲出し、これによってもコンタクトレンズが外し易くなるものと考えられる。   As shown in FIG. 1, the corneal weight was significantly reduced in the test solution B having a high ionic strength. This indicates that water has decreased from within the cornea. From this result, it is considered that water is exuded from the cornea between the contact lens and the cornea due to the solution having a high ionic strength, which also facilitates the removal of the contact lens.

[製剤実施例1] コンタクトレンズ取り外し用点眼液
次の処方に従い、常法により点眼液を調製した。
塩化ナトリウム・・・・・・・・・0.1g
塩酸または水酸化ナトリウム・・・適量
精製水・・・・・・・・・・・・・全量100mL
pH・・・・・・・・・・・・・・7.4
[Formulation Example 1] Ophthalmic Solution for Removing Contact Lenses An ophthalmic solution was prepared by a conventional method according to the following prescription.
Sodium chloride ... 0.1g
Hydrochloric acid or sodium hydroxide ... appropriate amount of purified water ... 100mL in total
pH ... 7.4

[製剤実施例2] コンタクトレンズ取り外し用点眼液
次の処方に従い、常法により点眼液を調製した。
塩化ナトリウム・・・・・・・・・3g
塩酸または水酸化ナトリウム・・・適量
精製水・・・・・・・・・・・・・全量100mL
pH・・・・・・・・・・・・・・7.2
[Formulation Example 2] Ophthalmic solution for removing contact lens An ophthalmic solution was prepared by a conventional method according to the following prescription.
Sodium chloride ... 3g
Hydrochloric acid or sodium hydroxide ... appropriate amount of purified water ... 100mL in total
pH ............ 7.2

[製剤実施例3] コンタクトレンズ取り外し用点眼液
次の処方に従い、常法により点眼液を調製した。
塩化ナトリウム・・・・・・・・・0.1g
クエン酸ナトリウム・・・・・・・0.2g
塩酸または水酸化ナトリウム・・・適量
精製水・・・・・・・・・・・・・全量100mL
pH・・・・・・・・・・・・・・7.0
[Formulation Example 3] Ophthalmic Solution for Removing Contact Lenses An ophthalmic solution was prepared by a conventional method according to the following prescription.
Sodium chloride ... 0.1g
Sodium citrate ... 0.2g
Hydrochloric acid or sodium hydroxide ... appropriate amount of purified water ... 100mL in total
pH: 7.0

[製剤実施例4] コンタクトレンズ取り外し用点眼液
次の処方に従い、常法により点眼液を調製した。
塩化ナトリウム・・・・・・・・・3g
クエン酸ナトリウム・・・・・・・0.2g
塩酸または水酸化ナトリウム・・・適量
精製水・・・・・・・・・・・・・全量100mL
pH・・・・・・・・・・・・・・7.0
[Formulation Example 4] Ophthalmic solution for removing contact lens An ophthalmic solution was prepared by a conventional method according to the following prescription.
Sodium chloride ... 3g
Sodium citrate ... 0.2g
Hydrochloric acid or sodium hydroxide ... appropriate amount of purified water ... 100mL in total
pH: 7.0

[製剤実施例5] コンタクトレンズ取り外し用点眼液
次の処方に従い、常法により点眼液を調製した。
塩化ナトリウム・・・・・・・・・0.1g
クエン酸ナトリウム・・・・・・・0.2g
塩酸または水酸化ナトリウム・・・適量
精製水・・・・・・・・・・・・・全量100mL
pH・・・・・・・・・・・・・・5.0
[Formulation Example 5] An ophthalmic solution for removing a contact lens An ophthalmic solution was prepared by a conventional method according to the following prescription.
Sodium chloride ... 0.1g
Sodium citrate ... 0.2g
Hydrochloric acid or sodium hydroxide ... appropriate amount of purified water ... 100mL in total
pH ... 5.0

[製剤実施例6] コンタクトレンズ取り外し用点眼液
次の処方に従い、常法により点眼液を調製した。
塩化ナトリウム・・・・・・・・・3g
クエン酸ナトリウム・・・・・・・0.2g
塩酸または水酸化ナトリウム・・・適量
精製水・・・・・・・・・・・・・全量100mL
pH・・・・・・・・・・・・・・5.0
[Formulation Example 6] Ophthalmic Solution for Removing Contact Lenses An ophthalmic solution was prepared by a conventional method according to the following prescription.
Sodium chloride ... 3g
Sodium citrate ... 0.2g
Hydrochloric acid or sodium hydroxide ... appropriate amount of purified water ... 100mL in total
pH ... 5.0

[製剤実施例7] コンタクトレンズ取り外し用点眼液
次の処方に従い、常法により点眼液を調製する。
塩化ナトリウム・・・・・・・・・0.1g
クエン酸ナトリウム・・・・・・・0.2g
コンドロイチン硫酸ナトリウム・・0.1g
酢酸d−α−トコフェロール・・・0.025g
塩酸ピリドキシン・・・・・・・・0.05g
L−アスパラギン酸カリウム・・・0.5g
エデト酸ナトリウム・・・・・・・0.01g
塩酸または水酸化ナトリウム・・・適量
精製水・・・・・・・・・・・・・全量100mL
pH・・・・・・・・・・・・・・7.0
[Preparation Example 7] Ophthalmic solution for removing contact lens An ophthalmic solution is prepared by a conventional method according to the following prescription.
Sodium chloride ... 0.1g
Sodium citrate ... 0.2g
Chondroitin sulfate sodium salt 0.1g
Acetic acid d-α-tocopherol: 0.025 g
Pyridoxine hydrochloride: 0.05g
L-aspartate potassium 0.5g
Edetate sodium ... 0.01g
Hydrochloric acid or sodium hydroxide ... appropriate amount of purified water ... 100mL in total
pH: 7.0

[製剤実施例8] コンタクトレンズ取り外し用点眼液
次の処方に従い、常法により点眼液を調製する。
塩化ナトリウム・・・・・・・・・0.1g
クエン酸ナトリウム・・・・・・・0.2g
ヒアルロン酸ナトリウム・・・・・0.1g
酢酸d−α−トコフェロール・・・0.025g
塩酸ピリドキシン・・・・・・・・0.05g
アミノエチルスルホン酸・・・・・0.5g
クロロブタノール・・・・・・・・0.2g
ソルビン酸・・・・・・・・・・・0.1g
塩酸または水酸化ナトリウム・・・適量
精製水・・・・・・・・・・・・・全量100mL
pH・・・・・・・・・・・・・・5.5
[Formulation Example 8] Ophthalmic solution for removing contact lens An ophthalmic solution is prepared by a conventional method according to the following prescription.
Sodium chloride ... 0.1g
Sodium citrate ... 0.2g
Sodium hyaluronate 0.1g
Acetic acid d-α-tocopherol: 0.025 g
Pyridoxine hydrochloride: 0.05g
Aminoethylsulfonic acid 0.5g
Chlorobutanol ... 0.2g
Sorbic acid ... 0.1g
Hydrochloric acid or sodium hydroxide ... appropriate amount of purified water ... 100mL in total
pH ... 5.5

本発明によれば、角膜表面に粘着して取り外し難くなったコンタクトレンズの取り外しを容易にする眼科組成物を提供することができる。   ADVANTAGE OF THE INVENTION According to this invention, the ophthalmic composition which makes easy removal of the contact lens which adhered to the cornea surface and became difficult to remove can be provided.

試験例2におけるウサギ角膜重量変化を示すグラフである。各値は平均+標準偏差を示す(n=3)。*はステューデントのT検定による試験液Aに対する有意差p<0.0005を表す。6 is a graph showing changes in rabbit cornea weight in Test Example 2. Each value represents mean + standard deviation (n = 3). * Represents a significant difference p <0.0005 with respect to test solution A by Student's T test.

Claims (3)

イオン強度が0.01〜0.12又は0.29〜0.56の水性組成物である、コンタクトレンズ取り外し用眼科組成物。   An ophthalmic composition for removing a contact lens, which is an aqueous composition having an ionic strength of 0.01 to 0.12 or 0.29 to 0.56. 角膜保護剤、ビタミン類、アミノ酸からなる群から選択される少なくとも1種の医薬成分を更に含有してなる、請求項1記載の組成物。   The composition according to claim 1, further comprising at least one pharmaceutical ingredient selected from the group consisting of a corneal protective agent, vitamins, and amino acids. 点眼剤である請求項1又は2記載の組成物。
The composition according to claim 1 or 2, which is an eye drop.
JP2004276179A 2004-09-22 2004-09-22 Contact lens removal ophthalmic composition Expired - Fee Related JP4642420B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004276179A JP4642420B2 (en) 2004-09-22 2004-09-22 Contact lens removal ophthalmic composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004276179A JP4642420B2 (en) 2004-09-22 2004-09-22 Contact lens removal ophthalmic composition

Publications (3)

Publication Number Publication Date
JP2006089403A true JP2006089403A (en) 2006-04-06
JP2006089403A5 JP2006089403A5 (en) 2007-11-01
JP4642420B2 JP4642420B2 (en) 2011-03-02

Family

ID=36230720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004276179A Expired - Fee Related JP4642420B2 (en) 2004-09-22 2004-09-22 Contact lens removal ophthalmic composition

Country Status (1)

Country Link
JP (1) JP4642420B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007088783A1 (en) * 2006-02-02 2007-08-09 Menicon Co., Ltd. Eye drop/wearing fluid for soft contact lenses
WO2008086270A2 (en) * 2007-01-05 2008-07-17 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
JP2014074071A (en) * 2008-09-03 2014-04-24 Alcon Research Ltd Pharmaceutical composition having relatively low ionic strength
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US9585394B2 (en) 2000-11-08 2017-03-07 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US10064410B2 (en) 2000-11-08 2018-09-04 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US10595532B2 (en) 2000-11-08 2020-03-24 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
WO2007088783A1 (en) * 2006-02-02 2007-08-09 Menicon Co., Ltd. Eye drop/wearing fluid for soft contact lenses
WO2008086270A2 (en) * 2007-01-05 2008-07-17 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
WO2008086270A3 (en) * 2007-01-05 2009-08-27 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
JP2014074071A (en) * 2008-09-03 2014-04-24 Alcon Research Ltd Pharmaceutical composition having relatively low ionic strength

Also Published As

Publication number Publication date
JP4642420B2 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
JP5650947B2 (en) Ophthalmic composition for ionic silicone hydrogel contact lens
MX2011009802A (en) Ophthalmic formulations of cetirizine and methods of use.
JPWO2006049250A1 (en) Intraocular transfer-promoting aqueous eye drops
JP2018203792A (en) Agent for improving foreign matter feeling of eyes
JP2011116686A (en) Ophthalmologic composition for silicone hydrogel contact lens
JP2015071554A (en) Olopatadine-containing eye drops
TW201818922A (en) Aqueous liquid medicine
JP2020125318A (en) Eye drop
JP2020073484A (en) Ophthalmic composition
JP5616589B2 (en) Eye drops for nonionic silicone hydrogel contact lenses
JP4642420B2 (en) Contact lens removal ophthalmic composition
JP6449774B2 (en) Ophthalmic composition for zwitterionic soft contact lenses
JP4904687B2 (en) Ophthalmic composition
JP2011111441A (en) Ophthalmic composition for nonionic silicone hydrogel contact lens
JP2007070350A (en) Preparation for ocular-mucous membrane application
JP5650864B2 (en) Nonionic silicone hydrogel contact lens ophthalmic composition
JP2007023020A (en) Preparation for ocular mucosa application
JP2005037928A (en) Composition of contact lense
JP4462406B2 (en) Soft contact lens remover
JP5506357B2 (en) Ophthalmic composition for silicone hydrogel contact lens
JP2009084235A (en) Ophthalmologic anti-congestive agent and anti-congestive ophthalmologic composition
JPWO2015041192A1 (en) Ophthalmic composition for anionic soft contact lenses
TWI623314B (en) Ophthalmic composition for zwitterionic soft contact lens
TWI626060B (en) Ophthalmic composition for zwitterionic soft contact lens
JP5689200B2 (en) Ophthalmic composition for silicone hydrogel contact lens

Legal Events

Date Code Title Description
A521 Written amendment

Effective date: 20070918

Free format text: JAPANESE INTERMEDIATE CODE: A523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Effective date: 20101102

Free format text: JAPANESE INTERMEDIATE CODE: A01

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101201

R150 Certificate of patent (=grant) or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131210

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees